EC approves Sandoz’s biosimilar Ziextenzo for febrile neutropenia
Novartis unit Sandoz has received marketing authorisation from the European Commission (EC) for biosimilar Ziextenzo (pegfilgrastim). Ziextenzo is intended to cut down…
Novartis unit Sandoz has received marketing authorisation from the European Commission (EC) for biosimilar Ziextenzo (pegfilgrastim). Ziextenzo is intended to cut down…
India-based drugmaker Sun Pharmaceutical Industries has signed a definitive agreement to acquire Pola Pharma, a Japan-based pharma firm involved in…
The Mundipharma network of independent associated companies has received European Commission (EC) approval for the use of Pelmeg (pegfilgrastim) for…
Swedish research-based pharmaceutical and biotechnology company Camurus has received European Commission (EC) approval for weekly and monthly Buvidal injections to…
Taiwanese biopharma company OBI Pharma has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for…
Switzerland-based Santhera Pharmaceuticals has signed an agreement with Idorsia to acquire the option to exclusively in-license dissociative steroid vamorolone via…
Iceland-based Alvotech has signed a deal for commercialisation of its biosimilar portfolio in Japan in an exclusive partnership agreement with…